Spotlight Kratom Industry Dangers — While FDA Targets the Alternative, 7-OH
Two major national news outlets — USA Today and the New York Post
— published scathing new reports this week exposing the growing public health crisis fueled by
kratom and its unregulated derivatives. Together, the stories reveal a disturbing pattern: while
everyday Americans fall victim to addiction, withdrawal, and predatory marketing, federal
officials are refusing to go after the actual source of danger, instead targeting 7-
hydroxymitragynine (7-OH), an industry competitor that the FDA’s own databases have shown
to have far fewer adverse events.










